The following tests are considered experimental and investigational (not covered) because effectiveness not established:
Stool molecular genetic tests other than Cologuard (e.g., ColoCaller Test, ColoSure, PreGen-Plus)not covered (investigational)
Methylated Septin 9 (ColoVantage, Epi proColon)not covered (investigational)
Whole-blood DNA methylation markersnot covered (investigational)
MicroRNAsnot covered (investigational)
Chromoendoscopy or narrow-band imaging optical colonoscopynot covered (investigational)
Plasma/serum biomarkers (CRP, complement C3a, GATA5 and SFRP2 methylation, serum CD26, MMP-7, TIMP-1)not covered (investigational)
PolypDxnot covered (investigational)
CD3 immuno-stainingnot covered (investigational)
Full-spectrum endoscopy (FUSE) colonoscopynot covered (investigational)
Stool-based protein biomarkersnot covered (investigational)
Blood-based protein biomarkers (e.g., BeScreened-CRC)not covered (investigational)
Capsule endoscopynot covered (investigational)
Artificial intelligence-aided colonoscopy (including computer-aided colonoscopy)not covered (investigational)
SimpliPro Colon Testnot covered (investigational)
Fecal volatile organic compoundsnot covered (investigational)
Performance of multiple screening strategies simultaneously in same individual (eg, virtual colonoscopy every 5 years plus stool DNA every 3 years)not covered (investigational)
Screening beginning earlier than standard recommended ages for persons at increased risk due to smoking or obesitynot covered (investigational)
Screening for anal cytological abnormalities (anal Pap) or anal HPV infection — experimental and investigationalnot covered (investigational)